Transmedics Group Stock Price, News & Analysis

TransMedics Group (Nasdaq: TMDX) announced a favorable vote from the FDA Circulatory Systems Device Advisory Panel on April 6, 2021, for its OCS Heart System. The panel supported the device's benefits over risks with a vote of 12 to 5 and indicated reasonable assurance of its effectiveness and safety. The OCS Heart EXPAND trial achieved a primary effectiveness endpoint, successfully transplanting 84% of extended-criteria donor hearts. The company is optimistic about future FDA approval and plans to expand its heart transplantation capabilities.

TransMedics Group, Inc. (NASDAQ: TMDX) announced a halt in trading of its common stock as the FDA's Circulatory System Devices Panel meets to review its Organ Care System™ (OCS) Heart System. The OCS™ is designed to preserve a donated heart in a near-physiologic state for monitoring and eventual transplantation. The meeting is set for 9:00 a.m. ET, with more details available on the FDA's website. This review is crucial for advancing TransMedics' innovative technology aimed at improving organ transplantation outcomes.

TransMedics Group appointed Stephanie Lovell to its Board of Directors and the Nominating and Corporate Governance Committee, effective March 22, 2021. With over 30 years of experience in healthcare management and legal affairs, she currently serves as Executive Vice President and Chief Legal Officer for Blue Cross Blue Shield of Massachusetts. Lovell's expertise is expected to enhance TransMedics' strategy in the U.S. transplant market. The company aims to improve organ transplantation outcomes through innovative technologies that increase donor organ utilization.

TransMedics Group, Inc. (TMDX) reported a 26% increase in net revenue for Q4 2020, totaling $7.6 million, driven by a recovery in U.S. OCS Lung procedure volumes. For the full year, revenue rose by 9% to $25.6 million, with a gross margin of 65%. Operating expenses decreased to $43 million due to COVID-19 related reductions. The net loss narrowed to $6.3 million in Q4 and $28.7 million for the year. The company also expanded its National OCS Program and launched several clinical initiatives. A conference call is scheduled for March 2, 2021.

TransMedics Group, Inc. (Nasdaq: TMDX) announced the scheduling of a crucial FDA Advisory Panel meeting on April 6, 2021. This meeting will evaluate the company's premarket approval application for the OCS Heart System, a technology aimed at improving organ transplant procedures. CEO Waleed Hassanein expressed optimism about achieving a positive outcome from the FDA's review process. The company is recognized for its innovations in organ preservation and viability assessment, which seek to enhance the availability and quality of donor organs for critical transplant surgeries.

TransMedics Group (Nasdaq: TMDX), a leader in organ transplant technology, will present at the Cowen 41st Annual Healthcare Conference on March 3, 2021, at 3:20 p.m. EST. The virtual presentation aims to showcase their advancements in organ preservation and assessment, addressing the critical need for improved organ availability for transplantation. A live and archived webcast will be accessible via the TransMedics Investors website. Founded in Andover, Mass., TransMedics focuses on enhancing the viability of donor organs for patients with end-stage heart, lung, and liver failure.

TransMedics Group, Inc. (Nasdaq: TMDX) will announce its fourth quarter and full year 2020 financial results on March 2, 2021, after market close. A conference call will follow at 4:30 p.m. ET. The company specializes in organ transplant therapy and aims to improve organ quality and viability assessment. Investors can access the conference by calling (833) 378-1026 domestically or (236) 712-2500 internationally, using Conference ID: 3751905. A webcast will be available on their Investor website.

TransMedics Group (Nasdaq: TMDX) announced its management will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2020, at 5:20 p.m. EST. The company specializes in transforming organ transplant therapy through portable extracorporeal warm perfusion technology.

The presentation will be accessible live and in archive via the Investors section of their website.

TransMedics Group announced the appointment of Merilee Raines to its Board of Directors and the Audit Committee, effective January 1, 2021. She will serve as Chair of the Audit Committee starting June 1, 2021. With over 30 years of executive experience, including a significant tenure as CFO at IDEXX Laboratories, Raines is expected to contribute valuable insights as TransMedics aims to enhance its position in the organ transplantation market. CEO Waleed Hassanein expressed confidence in her role for the company's future growth.